Glucocorticoids are widely used in primary-care veterinary practices. The study aimed to quantify the usage of systemic glucocorticoids (SGC) in dogs in UK using primary-care treatment records recorded during 2013 in the VetCompass™ Programme. From a study population of 455,557 dogs, 28,472 dogs (6.2%, 95%CI 6.2-6.3) received a total of 50,971 systemic glucocorticoid therapy events in 2013. Prednisolone represented the most frequently used oral preparation (27,362 events, 90.0% of oral events). Dexamethasone sodium phosphate was the most commonly used injectable agent (12,796 events, 62.7% of injectable events). The most common breed treated was Staffordshire Bull Terriers (2,236/28,472 dogs, 7.9%, 95% CI 7.5-8.2) and within-breed prevalence of SGC usage was 2,236/32,635, 6.9%, 95% CI 6.6-7.1.
Introduction
Glucocorticoids are a potent class of corticosteroids that are widely used in veterinary clinical management as anti-inflammatory and immunosuppressive agents, which can also induce adverse effects (1) . Additional uses include treatment for allergy/anaphylaxis, hypoadrenocorticism, neoplasia (lymphoma) and brain trauma (historically). The onset, duration and glucocorticoid potency (reflected in the dose) of effect depends on both the active substance and the formulation. There are several injectable and oral preparations available in the UK, containing corticosteroids of intermediate duration of action, such as prednisolone and methylprednisolone and long duration of action, such as dexamethasone. The duration of action of these drugs may be prolonged by their formulation (especially if injected as poorly soluble esters).
Few studies have quantified and described the usage of glucocorticoids in dogs in the UK. A study of 3 primary-care practices in England estimated that systemic glucocorticoids (SGC) were prescribed for approximately 15% of all dogs that received at least one medication (2) .
Of these, 1,497 (50.8%) had oral therapy, 1,227 (42.1%) had parenteral therapy and 207 (7.1%) had both oral and parenteral treatment. However, this work did not evaluate the proportion of all dogs under veterinary care that received glucocorticoid therapy, studying only those that had received some form of medication, and was based on a small sample of practices. Other work reported systemic glucocorticoid usage specifically within primary-care treatment of skin disease and reported that 162 of 795 skin cases (20%) received glucocorticoids as part of their therapeutic management (3) . These previous studies were based on a small sample size and may have introduced bias and limited the generalisability of results to the wider population.
Glucocorticoid administration has been associated with various adverse effects, including vomiting, diarrhoea, weight gain or loss, polyuria, polydipsia, delayed wound healing, immunosuppression and predisposition to infection, highlighting the value of reporting on current usage in veterinary clinical practice (4) . Long-term glucocorticoid treatment has been associated with increased risk of urinary tract infection (UTI) (5, 6 ).
However, current evidence on usage levels that are generalizable to the overall caseloads seen in primary-care practice in the UK is currently unavailable. Routine data collection over time across a large group of practices participating within the VetCompass™ Programme would facilitate evaluation of current usage levels. This study aimed to quantify and describe the usage of glucocorticoids across a large group of primary-care veterinary practices in the UK and provide benchmark results that can assist clinical audit in general practice. The current study did not aim to evaluate the underlying conditions for SGC treatment.
Materials and methods
The study population included all dogs under primary veterinary care during 2013 at exclusively primary-care small animal practices participating in the VetCompass™ Programme. The year 2013 was selected for study because it was the latest year with that a full available demographic dataset at the time when this study started. Dogs under veterinary care
were defined as those with either i) at least one electronic patient record (EPR) episode of care (summary diagnosis term, free-text clinical note, treatment or bodyweight) recorded during 2013 or ii) at least one EPR recorded both before and after 2013. The VetCompass™ Programme collates anonymised EPR data from primary-care veterinary practices in the UK for epidemiological research (7) . Dataset available for the study included species, breed, date of birth, sex, bodyweight, neuter status and treatments administered and dispensed with relevant dates.
A cohort study design was used to estimate the one-year period prevalence (2013) of systemic glucocorticoid (SGC) usage in dogs under veterinary care in the UK (8, 9) . Assuming a UK dog population of 8 million dogs (10) , sample size calculations estimated that a sample of approximately 180,000 dogs would be required to estimate an expected 5.0% level of usage of SGC with a precision of 0.1% at a 95% confidence level (11) . Ethics approval was obtained from the RVC Ethics and Welfare Committee (URN 2015 1369).
A SGC was defined as any glucocorticoid preparation administered by injection, oral tablets or oral suspension. Inclusion criteria for SGC usage required that the systemic glucocorticoid was either administered or dispensed during 2013. A comprehensive list of active substance and brand names for systemic glucocorticoids relevant to the UK companion animal veterinary market was generated by searching the Veterinary Medicines Directorate (VMD), British Small Animal Veterinary Association (BSAVA) formulary (12) and National Office for Animal Health (NOAH) veterinary products databases (13). A list of search terms was derived from these chemical and brand names that reliably identified usage for all systemic glucocorticoids within the treatment field of the VetCompass™ database (Appendix 2).
Glucocorticoid case finding involved initial screening of the treatment fields of all dogs within the study population for any treatment record that may have been a SGC using these search terms. A list of animal unique identification codes for these candidate cases for SGC usage was generated and treatment data (date, drug, volume/number of tablets, dosage instructions) on all treatments of any type during 2013 were extracted from the overall VetCompass™ database to an Excel format. Duplicates from the drug field were removed and all remaining dispensing terms used were manually coded as SGC (yes/no) to create a master list of SGC dispensing terms. All treatments from every candidate dog were then classified as either SGC or non-SGC using this master dispensing term list to identify all dogs from the overall study population with at least one SGC administered or dispensed during
2013.
A new systemic glucocorticoid episode was defined as usage of a systemic glucocorticoid A purebred variable categorised all dogs of recognisable breeds as 'purebred' and the remaining dogs as 'crossbred' (14) . A breed variable included individual breeds with 300 or more dogs receiving at least one SGC, a grouped category of all remaining purebreds and a general grouping of crossbred dogs. This approach was taken to allow focus on commonly treated breeds and to quantify usage with reasonable levels of precision (15) . period prevalence with 95% confidence intervals (CI) described the probability of SGC usage at least once during 2013 for all study dogs. The CI estimates were derived from standard errors based on approximation to the normal distribution for disorders with ten or more events (16) .
Demographic characteristics and prevalence of SGC usage in 2013 were reported by purebred status, common breeds, sex, neuter, insurance, adult age and adult bodyweight with 95% CIs.
Systemic glucocorticoid usage was classified by bodyweight and route of administration based on the dogs that received at least one treatment in 2013.
Results
The were neutered (Table 2) The most common age group that received SGC was more than 8 years [8, These conditions could potentially be treated with anti-inflammatories. Given that the most common clinical application of SGCs are as anti-inflammatory and immunosuppressive agents (1, 20) , breed-based results may be useful to identify breeds that are more likely to suffer inflammatory conditions and therefore also contribute to ongoing efforts to understand and prioritise breed health (21) . The current study did not aim to evaluate the underlying conditions for SGC treatment; further work to evaluate these conditions as well as the outcomes from therapy could provide further perspectives on breed health and welfare.
Older dogs were more likely to receive systemic glucocorticoids with dogs 8 years and older having a prevalence of 8.7% within the age category of the whole population and 31.4 % of the treated dogs. This is consistent with a previous study in which dogs were found to receive systemic glucocorticoid therapy more than puppies and young adults (2) . These results suggest that inflammatory conditions are more likely to develop with age and therefore older dogs are most likely to require systemic glucocorticoid therapy. A previous study of Swedish dogs reported that 10-year-old dogs had twice the odds of inflammatory conditions compared to 2-year-old dogs (22) .
Prednisolone was the most frequently used oral systemic glucocorticoid (90.0% of all oral SGC events) followed by methylprednisolone (9.7%). Prednisolone is either prescribed at antiinflammatory doses (0.5 to 1mg/kg/24h, tapered down to 0.25 to 0.5mg/kg/48h) or at immunosuppressive doses (1 to 2mg/kg/24, tapered down to 0.5mg/kg/48h or the lowest effective dose while assessing for clinical relapse) (12) . In a previous study in a small animal hospital in UK, prednisolone was administered twice daily to assess the potential relapse in dogs with steroid responsive meningitis-arteritis (23) . A previous smaller study of 3 practices in UK reported that, in dogs receiving oral SGCs, prednisolone (73.6%) and methylprednisolone (23.1%) were the most commonly used drugs (2) . It is possible that prescribing habits are highly individual to veterinarians and to practices. This may explain the substantial differences between the older smaller study and the current study results, and highlights the benefits from 'Big Data' analyses of merged datasets from multiple practices to be more representative of usage patterns across UK practice attending-dogs.
The current study reported that dexamethasone sodium phosphate was the most commonly used injectable therapeutic (62.7%). This ranking is in agreement with the earlier primary-care study that also reported dexamethasone sodium phosphate as the most common injectable therapeutic used in dogs (2) . Dexamethasone sodium phosphate is used widely in veterinary practices because it has good efficacy and a medium duration of action (48 hours). Blood cortisol levels have been shown to be suppressed with dexamethasone at 24 hours following injection (24) . Intermediate-duration injectable formulations of dexamethasone (ester of isonicotinate and or phenylpropionate combined with sodium phosphate) were only used in one third of the injections. The use of the long acting methylprednisolone acetate ester was rare, and the fast acting methylprednisolone sodium succinate salt was practically never used.
The study had some limitations. As previously described, these data were not recorded primarily for research purposes and thus were limited by some missing data as well as reliance on accurate and thorough record-keeping of the clinicians (25) . The study did not include the indication and underlying conditions for treated dogs, which could have offered a more complete picture to explain the patterns of usage in UK dogs. Knowledge of the prescribed daily doses (mg/kg) could help to define the intended therapeutic effect (high "shock" dose, immunosuppression, anti-inflammatory daily or alternate days) but the variable recording formats of dispensing events across the thousands of animals in the study (for example, start 1 tablet twice a day reduce to 1 daily then to 1 every other day) constrained the extraction of these data.
Conclusion
In conclusion, systemic glucocorticoids constitute a commonly used element of the therapeutic armamentarium of primary-care practitioners, with just over 6% of dogs under veterinary care receiving at least one systemic glucocorticoid annually. Certain breeds such as Staffordshire
Bull Terriers (7.9%, 95% CI 7.5-8.2), Labrador Retrievers (7.3%, 95% CI 7.0-7.6), and West
Highland White Terriers (6.0%, 95% CI 5.8-6.3) have an especially high prevalence of systemic glucocorticoid usage. Older dogs and dogs with higher adult bodyweight were more likely to be treated with systemic glucocorticoids. Prednisolone was the most frequent oral and dexamethasone sodium phosphate was the most common injectable systemic glucocorticoid. 
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